RNAC today
$6.36-$0.52 (-7.63%)close Nov 12, 2026Trend
DailyUptrend (starting)
4 hourExpanding
1 hourLeaning Bearish
15 minStrong Bearish
5 minStrong Bearish
Daily trend turns down below $6.01
Key levels
Resistance$7.90
Resistance$6.97
Support$6.20
Support$5.60
Latest news & SEC filings
EarningsCartesian Therapeutics Posts Q3 2026 Financials, Business Update
EarningsCartesian Therapeutics posts smaller Q3 loss than analysts expected
All RNAC news →About Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage biotechnology company developing cell therapies for autoimmune diseases. Its lead candidate, Descartes-08, is an autologous mRNA CAR-T therapy designed to be given as outpatient infusions without preconditioning chemotherapy. The company is testing it in generalized myasthenia gravis, myositis, and juvenile dermatomyositis, and it operates in the United States.
Based on the company's 10-K filed Mar 9, 2026.
Nasdaq · Healthcare
Cartesian Therapeutics, Inc. (RNAC)
What Is the Price Target for RNAC?
SEPT Low Target
$25.00
SEPT Mid Target
$25.00
SEPT High Target
$25.00
Analyst Consensus
$25.00
Is RNAC a Buy or Sell Right Now?
Thesis
- •Revenue growing -92.8% YoY with DECLINING trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for RNAC.
Start Free Trial →Is RNAC Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$25.00
17
Moat Score
NONE
1/9
Piotroski Score
-4.8
Altman Z-Score
What Is Smart Money Doing with RNAC?
Insider Signal
NEUTRAL
0 buys / 3 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →RNAC Growth Story
Revenue YoY
-92.8%
3yr Revenue CAGR
-70.7%
EPS Growth YoY
-11.8%
FCF Growth YoY
-142.3%
Revenue Trend
DECLINING
Dark Pool Trades for RNAC
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for RNAC, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:26:21 | $6.30 | 15,333 | $$97K | BUY |
| 18:52:40 | $6.25 | 1,100 | $$7K | BUY |
| 18:12:06 | $6.33 | 2,996 | $$19K | BUY |
| 17:59:09 | $6.31 | 2,000 | $$13K | SELL |
| 17:34:33 | $6.14 | 1,300 | $$8K | SELL |
5 dark pool trades shown · $$143K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Cartesian Therapeutics, Inc. (RNAC) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →RNAC — frequently asked questions
What is RNAC stock price today?
Cartesian Therapeutics, Inc. (RNAC) is at $6.36, down 7.63% (-$0.52) at the Nov 12, 2026 close.
Why is RNAC stock moving today?
Latest RNAC news — Nov 5, 2026: Cartesian Therapeutics Posts Q3 2026 Financials, Business Update · Nov 5, 2026: Cartesian Therapeutics posts smaller Q3 loss than analysts expected
What is the RNAC price target?
The average analyst price target for RNAC is $25.00, ranging from $25 to $25, based on 2 analysts.
What do analysts rate RNAC?
Analyst ratings for RNAC: 0 Buy, 9 Hold, 0 Sell — consensus Hold.
Did RNAC beat earnings?
RNAC last reported on Aug 6, 2026: EPS $0.46 vs -$0.88 expected — a beat of 152.4%.
Does RNAC pay a dividend?
RNAC does not currently pay a dividend.
What are RNAC support and resistance levels?
Support: $6.20, $5.60. Resistance: $6.97, $7.90, $8.80.
What are insiders doing with RNAC?
Insider activity: NEUTRAL, 0 buys and 3 sells in the last 90 days.
What is the latest news on RNAC?
Nov 5, 2026: Cartesian Therapeutics Posts Q3 2026 Financials, Business Update · Nov 5, 2026: Cartesian Therapeutics posts smaller Q3 loss than analysts expected